Header Logo

FRANK V FOSSELLA

TitleProfessor
InstitutionMD Anderson
DepartmentThoracic Head & Neck Medical Oncology
Address1400 Holcombe Blvd
Houston TX 77030-4008
vCardDownload vCard

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Zhou N, Leung CH, William WN, Weissferdt A, Pataer A, Godoy MCB, Carter BW, Fossella FV, Tsao AS, Blumenschein GR, Le X, Zhang J, Skoulidis F, Kurie JM, Altan M, Lu C, Glisson BS, Byers LA, Elamin YY, Mehran RJ, Rice DC, Walsh GL, Hofstetter WL, Roth JA, Tran HT, Wu J, Solis Soto LM, Kadara H, Swisher SG, Vaporciyan AA, Gibbons DL, Lin HY, Lee JJ, Heymach JV, Negrao MV, Sepesi B, Cascone T. Impact of select actionable genomic alterations on efficacy of neoadjuvant immunotherapy in resectable non-small cell lung cancer. J Immunother Cancer. 2024 Oct 23; 12(10). PMID: 39448200; PMCID: PMC11499765.
      Citations:    Fields:    Translation:Humans
    2. Pan K, Owens J, Elamin Y, Lu C, Routbort M, Zhang J, Fossella F, Negrao MV, Altan M, Pozadzides J, Skoulidis F, Tsao A, Cascone T, Heymach JV, Ostrin E, Le X, Pan K, Owens J, Elamin Y, Lu C, Routbort M, Zhang J, Fossella F, Negrao MV, Altan M, Pozadzides J, Skoulidis F, Tsao A, Cascone T, Heymach JV, Ostrin E, Le X. Mutational Characteristics and Clinical Outcomes for Lung Adenocarcinoma With EGFR Germline Mutations. J Thorac Oncol. 2024 Oct; 19(10):1438-1448. PMID: 38866326.
      Citations: 1     Fields:    Translation:Humans
    3. Chang JY, Lin SH, Dong W, Liao Z, Gandhi SJ, Gay CM, Zhang J, Chun SG, Elamin YY, Fossella FV, Blumenschein G, Cascone T, Le X, Pozadzides JV, Tsao A, Verma V, Welsh JW, Chen AB, Altan M, Mehran RJ, Vaporciyan AA, Swisher SG, Balter PA, Fujimoto J, Wistuba II, Feng L, Lee JJ, Heymach JV. Stereotactic ablative radiotherapy with or without immunotherapy for early-stage or isolated lung parenchymal recurrent node-negative non-small-cell lung cancer: an open-label, randomised, phase 2 trial. Lancet. 2023 09 09; 402(10405):871-881. PMID: 37478883; PMCID: PMC10529504.
      Citations: 13     Fields:    Translation:HumansCTClinical Trials
    4. Wang K, Du R, Roy-Chowdhuri S, Li ZT, Hong L, Vokes N, Elamin YY, Hume CB, Skoulidis F, Gay CM, Blumenschein G, Fossella FV, Tsao A, Zhang J, Karachaliou N, O'Brate A, Gann CN, Lewis J, Rinsurongkawong W, Lee JJ, Gibbons DL, Vaporciyan AA, Heymach JV, Altan M, Le X. Brief Report: Clinical Response, Toxicity, and Resistance Mechanisms to Osimertinib Plus MET Inhibitors in Patients With EGFR-Mutant MET-Amplified NSCLC. JTO Clin Res Rep. 2023 Aug; 4(8):100533. PMID: 37649681; PMCID: PMC10462815.
      Citations: 1     
    5. Hanna N, Shepherd FA, Fossella FV, Pereira JR, De Marinis F, von Pawel J, Gatzemeier U, Tsao TCY, Pless M, Muller T, Lim HL, Desch C, Szondy K, Gervais R, Manegold C, Paul S, Paoletti P, Einhorn L, Bunn PA. Randomized Phase III Trial of Pemetrexed Versus Docetaxel in Patients With Non-Small-Cell Lung Cancer Previously Treated With Chemotherapy. J Clin Oncol. 2023 05 20; 41(15):2682-2690. PMID: 37196429.
      Citations: 3     Fields:    
    6. Altan M, Tu J, Milton DR, Yilmaz B, Tian Y, Fossella FV, Mott FE, Blumenschein GR, Stephen B, Karp DD, Meric-Bernstam F, Heymach JV, Naing A. Safety, tolerability, and clinical activity of selinexor in combination with pembrolizumab in treatment of metastatic non-small cell lung cancer. Cancer. 2023 09 01; 129(17):2685-2693. PMID: 37129197.
      Citations:    Fields:    Translation:Humans
    7. Cascone T, Leung CH, Weissferdt A, Pataer A, Carter BW, Godoy MCB, Feldman H, William WN, Xi Y, Basu S, Sun JJ, Yadav SS, Rojas Alvarez FR, Lee Y, Mishra AK, Chen L, Pradhan M, Guo H, Sinjab A, Zhou N, Negrao MV, Le X, Gay CM, Tsao AS, Byers LA, Altan M, Glisson BS, Fossella FV, Elamin YY, Blumenschein G, Zhang J, Skoulidis F, Wu J, Mehran RJ, Rice DC, Walsh GL, Hofstetter WL, Rajaram R, Antonoff MB, Fujimoto J, Solis LM, Parra ER, Haymaker C, Wistuba II, Swisher SG, Vaporciyan AA, Lin HY, Wang J, Gibbons DL, Jack Lee J, Ajami NJ, Wargo JA, Allison JP, Sharma P, Kadara H, Heymach JV, Sepesi B. Neoadjuvant chemotherapy plus nivolumab with or without ipilimumab in operable non-small cell lung cancer: the phase 2 platform NEOSTAR trial. Nat Med. 2023 03; 29(3):593-604. PMID: 36928818; PMCID: PMC10033402.
      Citations: 11     Fields:    Translation:HumansCTClinical Trials
    8. Offodile AC, Delgado D, Lin YL, Geyen D, Miller CJ, Jain S, Finder JP, Shete S, Fossella FV, Overman MJ, Peterson SK. Integration of Remote Symptom and Biometric Monitoring Into the Care of Adult Patients With Cancer Receiving Chemotherapy-A Decentralized Feasibility Pilot Study. JCO Oncol Pract. 2023 06; 19(6):e811-e821. PMID: 36821818; PMCID: PMC10332844.
      Citations:    Fields:    Translation:Humans
    9. Liu Y, Yao L, Kalhor N, Carter BW, Altan M, Blumenschein G, Byers LA, Fossella F, Gibbons DL, Kurie JM, Lu C, Skoulidis F, Chang JY, Liao Z, Gomez DR, O'Reilly M, Heymach JV, Tsao AS, Lin SH. Final efficacy outcomes of atezolizumab with chemoradiation for unresectable NSCLC: The phase II DETERRED trial. Lung Cancer. 2022 Dec; 174:112-117. PMID: 36371941.
      Citations:    Fields:    
    10. Hui D, Puac V, Shelal Z, Dev R, Hanneman SK, Jennings K, Ma H, Urbauer DL, Shete S, Fossella F, Liao Z, Blumenschein G, Chang JY, O'Reilly M, Gandhi SJ, Tsao A, Mahler DA, Bruera E. Effect of dexamethasone on dyspnoea in patients with cancer (ABCD): a parallel-group, double-blind, randomised, controlled trial. Lancet Oncol. 2022 10; 23(10):1321-1331. PMID: 36087590; PMCID: PMC10618956.
      Citations:    
    11. Elamin YY, Robichaux JP, Carter BW, Altan M, Tran H, Gibbons DL, Heeke S, Fossella FV, Lam VK, Le X, Negrao MV, Nilsson MB, Patel A, Vijayan RSK, Cross JB, Zhang J, Byers LA, Lu C, Cascone T, Feng L, Luthra R, San Lucas FA, Mantha G, Routbort M, Blumenschein G, Tsao AS, Heymach JV. Poziotinib for EGFR exon 20-mutant NSCLC: Clinical efficacy, resistance mechanisms, and impact of insertion location on drug sensitivity. Cancer Cell. 2022 07 11; 40(7):754-767.e6. PMID: 35820397; PMCID: PMC9667883.
      Citations:    Fields:    Translation:HumansCTClinical Trials
    12. Lin SH, Lin HY, Verma V, Xu-Welliver M, Thall PF, Yao L, Kim PY, Gombos DS, Kawedia JD, Komaki R, Gomez DR, Nguyen QN, O'Reilly MS, Lu C, Fossella FV, Skoulidis F, Zhang J, Tsao AS, Heymach JV, Blumenschein GR. Phase I Trial of Definitive Concurrent Chemoradiotherapy and Trametinib for KRAS-Mutated Non-Small Cell Lung Cancer. Cancer Treat Res Commun. 2022; 30:100514. PMID: 35051703; PMCID: PMC9259763.
      Citations:    Fields:    
    13. Malek AE, Khalil M, Hachem R, Chaftari AM, Fares J, Jiang Y, Kontoyiannis DP, Fossella F, Chaftari P, Mulanovich VE, Viola GM, Raad II. Impact of Checkpoint Inhibitor Immunotherapy, Primarily Pembrolizumab, on Infection Risk in Patients With Advanced Lung Cancer: A Comparative Retrospective Cohort Study. Clin Infect Dis. 2021 11 02; 73(9):e2697-e2704. PMID: 32564081.
      Citations: 2     Fields:    Translation:Humans
    14. Elamin YY, Robichaux JP, Carter BW, Altan M, Gibbons DL, Fossella FV, Lam VK, Patel AB, Negrao MV, Le X, Mott FE, Zhang J, Feng L, Blumenschein G, Tsao AS, Heymach JV. Poziotinib for Patients With HER2 Exon 20 Mutant Non-Small-Cell Lung Cancer: Results From a Phase II Trial. J Clin Oncol. 2022 03 01; 40(7):702-709. PMID: 34550757; PMCID: PMC8887948.
      Citations: 7     Fields:    Translation:HumansCTClinical Trials
    15. Tran HT, Lam VK, Elamin YY, Hong L, Colen R, Elshafeey NA, Hassan ISA, Altan M, Blumenschein GR, Rinsurongkawong W, Rivera MJ, Vasquez ME, Carter BW, Byers LE, Tsao AS, Gibbons DL, Fossella F, Glisson BS, Zhang J, Heymach JV. Clinical Outcomes in Non-Small-Cell Lung Cancer Patients Treated With EGFR-Tyrosine Kinase Inhibitors and Other Targeted Therapies Based on Tumor Versus Plasma Genomic Profiling. JCO Precis Oncol. 2021 08; 5. PMID: 34377884; PMCID: PMC8345916.
      Citations: 5     Fields:    Translation:Humans
    16. Patel RR, He K, Barsoumian HB, Chang JY, Tang C, Verma V, Comeaux N, Chun SG, Gandhi S, Truong MT, Erasmus JJ, Hong DS, Lee PP, Ning MS, Nguyen QN, Heymach JV, Altan M, Blumenschein G, Fossella FV, Sezen D, Chen D, Carter BW, Davies MA, Glitza IC, Diab A, Ferrarotto R, Cabanillas ME, Yuan Y, Shah SJ, Parra ER, Sun B, Cortez MA, Welsh JW. High-dose irradiation in combination with non-ablative low-dose radiation to treat metastatic disease after progression on immunotherapy: Results of a phase II trial. Radiother Oncol. 2021 09; 162:60-67. PMID: 34237343.
      Citations: 6     Fields:    Translation:HumansCTClinical Trials
    17. Cascone T, William WN, Weissferdt A, Leung CH, Lin HY, Pataer A, Godoy MCB, Carter BW, Federico L, Reuben A, Khan MAW, Dejima H, Francisco-Cruz A, Parra ER, Solis LM, Fujimoto J, Tran HT, Kalhor N, Fossella FV, Mott FE, Tsao AS, Blumenschein G, Le X, Zhang J, Skoulidis F, Kurie JM, Altan M, Lu C, Glisson BS, Byers LA, Elamin YY, Mehran RJ, Rice DC, Walsh GL, Hofstetter WL, Roth JA, Antonoff MB, Kadara H, Haymaker C, Bernatchez C, Ajami NJ, Jenq RR, Sharma P, Allison JP, Futreal A, Wargo JA, Wistuba II, Swisher SG, Lee JJ, Gibbons DL, Vaporciyan AA, Heymach JV, Sepesi B. Neoadjuvant nivolumab or nivolumab plus ipilimumab in operable non-small cell lung cancer: the phase 2 randomized NEOSTAR trial. Nat Med. 2021 03; 27(3):504-514. PMID: 33603241; PMCID: PMC8818318.
      Citations: 73     Fields:    Translation:HumansCTClinical Trials
    18. Gjyshi O, Xu T, Elhammali A, Boyce-Fappiano D, Chun SG, Gandhi S, Lee P, Chen AB, Lin SH, Chang JY, Tsao A, Gay CM, Zhu XR, Zhang X, Heymach JV, Fossella FV, Lu C, Nguyen QN, Liao Z. Toxicity and Survival After Intensity-Modulated Proton Therapy Versus Passive Scattering Proton Therapy for NSCLC. J Thorac Oncol. 2021 02; 16(2):269-277. PMID: 33198942; PMCID: PMC7855203.
      Citations: 4     Fields:    Translation:HumansCTClinical Trials
    19. Hong L, Negrao MV, Dibaj SS, Chen R, Reuben A, Bohac JM, Liu X, Skoulidis F, Gay CM, Cascone T, Mitchell KG, Tran HT, Le X, Byers LA, Sepesi B, Altan M, Elamin YY, Fossella FV, Kurie JM, Lu C, Mott FE, Tsao AS, Rinsurongkawong W, Lewis J, Gibbons DL, Glisson BS, Blumenschein GR, Roarty EB, Futreal PA, Wistuba II, Roth JA, Swisher SG, Papadimitrakopoulou VA, Heymach JV, Lee JJ, Simon GR, Zhang J. Programmed Death-Ligand 1 Heterogeneity and Its Impact on Benefit From Immune Checkpoint Inhibitors in NSCLC. J Thorac Oncol. 2020 09; 15(9):1449-1459. PMID: 32389639.
      Citations: 39     Fields:    Translation:Humans
    20. Cascone T, Sepesi B, Lin HY, Kalhor N, Parra ER, Jiang M, Godoy MCB, Zhang J, Fossella FV, Tsao AS, Lam VK, Lu C, Mott FE, Simon GR, Antonoff MB, Mehran RJ, Rice DC, Behrens C, Weissferdt A, Moran C, Vaporciyan AA, Lee JJ, Swisher SG, Gibbons DL, Wistuba II, William WN, Heymach JV. A Phase I/II Study of Neoadjuvant Cisplatin, Docetaxel, and Nintedanib for Resectable Non-Small Cell Lung Cancer. Clin Cancer Res. 2020 07 15; 26(14):3525-3536. PMID: 32193228; PMCID: PMC7446232.
      Citations: 7     Fields:    Translation:HumansCells
    21. Lin SH, Lin Y, Yao L, Kalhor N, Carter BW, Altan M, Blumenschein G, Byers LA, Fossella F, Gibbons DL, Kurie JM, Lu C, Simon G, Skoulidis F, Chang JY, Jeter MD, Liao Z, Gomez DR, O'Reilly M, Papadimitrakopoulou V, Thall P, Heymach JV, Tsao AS. Phase II Trial of Concurrent Atezolizumab With Chemoradiation for Unresectable NSCLC. J Thorac Oncol. 2020 02; 15(2):248-257. PMID: 31778797.
      Citations: 35     Fields:    Translation:HumansCTClinical Trials
    22. Tsao AS, Miao J, Wistuba II, Vogelzang NJ, Heymach JV, Fossella FV, Lu C, Velasco MR, Box-Noriega B, Hueftle JG, Gadgeel S, Redman MW, Gandara DR, Kelly K. Phase II Trial of Cediranib in Combination With Cisplatin and Pemetrexed in Chemotherapy-Na?ve Patients With Unresectable Malignant Pleural Mesothelioma (SWOG S0905). J Clin Oncol. 2019 10 01; 37(28):2537-2547. PMID: 31386610; PMCID: PMC7001793.
      Citations: 16     Fields:    Translation:HumansCTClinical Trials
    23. Hui D, Kilgore K, Park M, Liu D, Kim YJ, Park JC, Fossella F, Bruera E. Pattern and Predictors of Outpatient Palliative Care Referral Among Thoracic Medical Oncologists. Oncologist. 2018 10; 23(10):1230-1235. PMID: 29895629; PMCID: PMC6263132.
      Citations: 4     Fields:    Translation:Humans
    24. Liao Z, Lee JJ, Komaki R, Gomez DR, O'Reilly MS, Fossella FV, Blumenschein GR, Heymach JV, Vaporciyan AA, Swisher SG, Allen PK, Choi NC, DeLaney TF, Hahn SM, Cox JD, Lu CS, Mohan R. Bayesian Adaptive Randomization Trial of Passive Scattering Proton Therapy and Intensity-Modulated Photon Radiotherapy for Locally Advanced Non-Small-Cell Lung Cancer. J Clin Oncol. 2018 06 20; 36(18):1813-1822. PMID: 29293386; PMCID: PMC6008104.
      Citations: 98     Fields:    Translation:Humans
    25. Cascone T, Gold KA, Swisher SG, Liu DD, Fossella FV, Sepesi B, Pataer A, Weissferdt A, Kalhor N, Vaporciyan AA, Hofstetter WL, Wistuba II, Heymach JV, Kim ES, William WN. Induction Cisplatin Docetaxel Followed by Surgery and Erlotinib in Non-Small Cell Lung Cancer. Ann Thorac Surg. 2018 Feb; 105(2):418-424. PMID: 29217088; PMCID: PMC5783769.
      Citations: 12     Fields:    Translation:HumansCTClinical Trials
    26. Jeter MD, Gomez D, Nguyen QN, Komaki R, Zhang X, Zhu X, O'Reilly M, Fossella FV, Xu T, Wei X, Wang H, Yang W, Tsao A, Mohan R, Liao Z. Simultaneous Integrated Boost for Radiation Dose Escalation to the Gross Tumor Volume With Intensity Modulated (Photon) Radiation Therapy or Intensity Modulated Proton Therapy and Concurrent Chemotherapy for Stage II to III Non-Small Cell Lung Cancer: A Phase 1 Study. Int J Radiat Oncol Biol Phys. 2018 03 01; 100(3):730-737. PMID: 29248169; PMCID: PMC5846341.
      Citations: 9     Fields:    Translation:HumansCTClinical Trials
    27. Schvartsman G, Peng SA, Bis G, Lee JJ, Benveniste MFK, Zhang J, Roarty EB, Lacerda L, Swisher S, Heymach JV, Fossella FV, William WN. Response rates to single-agent chemotherapy after exposure to immune checkpoint inhibitors in advanced non-small cell lung cancer. Lung Cancer. 2017 10; 112:90-95. PMID: 29191606.
      Citations: 69     Fields:    Translation:Humans
    28. Papadimitrakopoulou V, Lee JJ, Wistuba II, Tsao AS, Fossella FV, Kalhor N, Gupta S, Byers LA, Izzo JG, Gettinger SN, Goldberg SB, Tang X, Miller VA, Skoulidis F, Gibbons DL, Shen L, Wei C, Diao L, Peng SA, Wang J, Tam AL, Coombes KR, Koo JS, Mauro DJ, Rubin EH, Heymach JV, Hong WK, Herbst RS. The BATTLE-2 Study: A Biomarker-Integrated Targeted Therapy Study in Previously Treated Patients With Advanced Non-Small-Cell Lung Cancer. J Clin Oncol. 2016 Oct 20; 34(30):3638-3647. PMID: 27480147; PMCID: PMC5065110.
      Citations: 67     Fields:    
    29. Waxman ES, Fossella FV. Biomarkers/Molecular Targets, Immunotherapy, and Treatments for Non-Small Cell Lung Cancer. J Adv Pract Oncol. 2016 Jul-Aug; 7(5):514-524. PMID: 29282427; PMCID: PMC5737399.
      Citations: 1     
    30. Hui D, Kilgore K, Frisbee-Hume S, Park M, Tsao A, Delgado Guay M, Lu C, William W, Pisters K, Eapen G, Fossella F, Amin S, Bruera E. Dexamethasone for Dyspnea in Cancer Patients: A Pilot Double-Blind, Randomized, Controlled Trial. J Pain Symptom Manage. 2016 07; 52(1):8-16.e1. PMID: 27330023; PMCID: PMC4958556.
      Citations: 14     Fields:    Translation:Humans
    31. Shah MH, Lorigan P, O'Brien ME, Fossella FV, Moore KN, Bhatia S, Kirby M, Woll PJ. Phase I study of IMGN901, a CD56-targeting antibody-drug conjugate, in patients with CD56-positive solid tumors. Invest New Drugs. 2016 06; 34(3):290-9. PMID: 26961907; PMCID: PMC4859861.
      Citations: 11     Fields:    Translation:HumansCTClinical Trials
    32. Hui D, Bansal S, Park M, Reddy A, Cortes J, Fossella F, Bruera E. Differences in attitudes and beliefs toward end-of-life care between hematologic and solid tumor oncology specialists. Ann Oncol. 2015 Jul; 26(7):1440-6. PMID: 26041765; PMCID: PMC4855240.
      Citations: 28     Fields:    Translation:Humans
    33. Gladish GW, Wei X, Kotamarti KR, Allen PK, Cox JD, O'Reilly MS, Erasmus JJ, Fossella FV, Komaki R, Gomez DR. Prognostic value of positron emission tomography/computed tomography findings in limited-stage small cell lung cancer before chemoradiation therapy. Am J Clin Oncol. 2014 Feb; 37(1):77-80. PMID: 23111360.
      Citations: 4     Fields:    Translation:Humans
    34. Saintigny P, Liu S, Kim ES, Tsao AS, Herbst RS, Alden C, Lee JJ, Tang X, Stewart DJ, Kies MS, Fossella FV, Tran HT, Mao L, Hicks ME, Erasmus J, Gupta S, Girard L, Peyton M, Diao L, Wang J, Davis SE, Minna JD, Wistuba I, Hong WK, Heymach JV, Lippman SM, Blumenschein GR. Comprehensive biomarker analysis and final efficacy results of sorafenib in the BATTLE trial. Clin Cancer Res. 2013 Dec 15; 19(24):6967-75. PMID: 24166906; PMCID: PMC3905243.
      Citations: 28     Fields:    Translation:Humans
    35. Milbury K, Badr H, Fossella F, Pisters KM, Carmack CL. Longitudinal associations between caregiver burden and patient and spouse distress in couples coping with lung cancer. Support Care Cancer. 2013 Sep; 21(9):2371-9. PMID: 23546537; PMCID: PMC4428561.
      Citations: 38     Fields:    Translation:Humans
    36. Squifflet P, Fossella F, Georgoulias V, Pujol JL, Douillard JY, Kudoh S, Pignon JP, Quinaux E, Buyse M, Laporte S, Baroux N. Prediction of survival benefits from progression-free survival benefits in advanced non-small-cell lung cancer: evidence from a meta-analysis of 2334 patients from 5 randomised trials. BMJ Open. 2013 Mar 13; 3(3). PMID: 23485717; PMCID: PMC3612819.
      Citations: 17     Fields:    
    37. Tsao AS, Liu S, Fujimoto J, Wistuba II, Lee JJ, Marom EM, Charnsangavej C, Fossella FV, Tran HT, Blumenschein GR, Papadimitrakopoulou V, Kies MS, Hong WK, Stewart DJ. Phase II trials of imatinib mesylate and docetaxel in patients with metastatic non-small cell lung cancer and head and neck squamous cell carcinoma. J Thorac Oncol. 2011 Dec; 6(12):2104-11. PMID: 21892101.
      Citations: 13     Fields:    Translation:HumansCTClinical Trials
    38. Kim ES, Herbst RS, Wistuba II, Lee JJ, Blumenschein GR, Tsao A, Stewart DJ, Hicks ME, Erasmus J, Gupta S, Alden CM, Liu S, Tang X, Khuri FR, Tran HT, Johnson BE, Heymach JV, Mao L, Fossella F, Kies MS, Papadimitrakopoulou V, Davis SE, Lippman SM, Hong WK. The BATTLE trial: personalizing therapy for lung cancer. Cancer Discov. 2011 Jun; 1(1):44-53. PMID: 22586319; PMCID: PMC4211116.
      Citations: 329     Fields:    Translation:HumansCTClinical Trials
    39. Blumenschein GR, Paulus R, Curran WJ, Robert F, Fossella F, Werner-Wasik M, Herbst RS, Doescher PO, Choy H, Komaki R. Phase II study of cetuximab in combination with chemoradiation in patients with stage IIIA/B non-small-cell lung cancer: RTOG 0324. J Clin Oncol. 2011 Jun 10; 29(17):2312-8. PMID: 21555682; PMCID: PMC3107747.
      Citations: 52     Fields:    Translation:HumansCTClinical Trials
    40. Shirvani SM, Komaki R, Heymach JV, Fossella FV, Chang JY. Positron emission tomography/computed tomography-guided intensity-modulated radiotherapy for limited-stage small-cell lung cancer. Int J Radiat Oncol Biol Phys. 2012 Jan 01; 82(1):e91-7. PMID: 21489716; PMCID: PMC3465842.
      Citations: 22     Fields:    Translation:Humans
    41. Blumenschein GR, Reck M, Fossella F, Stewart DJ, Lathia C, Pe?a C. Plasma biomarkers correlating with clinical outcome in a phase II study of sorafenib in advanced NSCLC. Cancer Biomark. 2011-2012; 10(6):287-98. PMID: 22820084.
      Citations: 3     Fields:    Translation:Humans
    42. Scagliotti G, Brodowicz T, Shepherd FA, Zielinski C, Vansteenkiste J, Manegold C, Simms L, Fossella F, Sugarman K, Belani CP. Treatment-by-histology interaction analyses in three phase III trials show superiority of pemetrexed in nonsquamous non-small cell lung cancer. J Thorac Oncol. 2011 Jan; 6(1):64-70. PMID: 21119545.
      Citations: 84     Fields:    Translation:Humans
    43. William WN, Uyeki J, Johnson FM, Feng L, Peeples BO, Fossella FV, Karp DD, Blumenschein GR, Stewart DJ, Glisson BS. Weekly alternating therapy with irinotecan plus cisplatin and etoposide plus cisplatin in the treatment of patients with extensive small cell lung carcinoma. Cancer. 2010 May 15; 116(10):2409-15. PMID: 20225329.
      Citations: 1     Fields:    Translation:HumansCTClinical Trials
    44. William WN, Kies MS, Fossella FV, Liu DD, Gladish G, Tse WH, Lee JJ, Hong WK, Lippman SM, Kim ES. Phase 2 study of carboplatin, docetaxel, and bevacizumab as frontline treatment for advanced nonsmall-cell lung cancer. Cancer. 2010 May 15; 116(10):2401-8. PMID: 20225327; PMCID: PMC5145307.
      Citations: 6     Fields:    Translation:HumansCTClinical Trials
    45. William WN, Khuri FR, Fossella FV, Glisson BS, Zinner RG, Lee JJ, Herbst RS, Lippman SM, Kim ES. Phase II study of vinorelbine and docetaxel in the treatment of advanced non-small-cell lung cancer as frontline and second-line therapy. Am J Clin Oncol. 2010 Apr; 33(2):148-52. PMID: 19687727; PMCID: PMC5118944.
      Citations: 4     Fields:    Translation:HumansCTClinical Trials
    46. Blumenschein GR, Gatzemeier U, Fossella F, Stewart DJ, Cupit L, Cihon F, O'Leary J, Reck M. Phase II, multicenter, uncontrolled trial of single-agent sorafenib in patients with relapsed or refractory, advanced non-small-cell lung cancer. J Clin Oncol. 2009 Sep 10; 27(26):4274-80. PMID: 19652055.
      Citations: 66     Fields:    Translation:HumansCTClinical Trials
    47. Scagliotti G, Hanna N, Fossella F, Sugarman K, Blatter J, Peterson P, Simms L, Shepherd FA. The differential efficacy of pemetrexed according to NSCLC histology: a review of two Phase III studies. Oncologist. 2009 Mar; 14(3):253-63. PMID: 19221167.
      Citations: 220     Fields:    Translation:HumansCTClinical Trials
    48. Rice D, Swisher S, Pisters K, Fossella F, Herbst R, Hofstetter W, Kies M, Komaki R, Lippman S, Mehran R, Roth J, Stewart D, Vaporciyan A, Walsh G, Cox J. Comment on "Treatment of non-small cell lung cancer stage IIIA: ACCP evidence-based clinical practice guidelines (2nd edition)". Chest. 2008 Dec; 134(6):1349. PMID: 19059972.
      Citations:    Fields:    Translation:Humans
    49. Carmack Taylor CL, Badr H, Lee JH, Fossella F, Pisters K, Gritz ER, Schover L. Lung cancer patients and their spouses: psychological and relationship functioning within 1 month of treatment initiation. Ann Behav Med. 2008 Oct; 36(2):129-40. PMID: 18797978; PMCID: PMC4454464.
      Citations: 48     Fields:    Translation:Humans
    50. Zinner RG, Komaki R, Cox JD, Glisson BS, Pisters KM, Herbst RS, Kies M, Liao Z, Hong WK, Fossella FV. Dose escalation of gemcitabine is possible with concurrent chest three-dimensional rather than two-dimensional radiotherapy: a phase I trial in patients with stage III non-small-cell lung cancer. Int J Radiat Oncol Biol Phys. 2009 Jan 01; 73(1):119-27. PMID: 18556142.
      Citations: 5     Fields:    Translation:HumansCTClinical Trials
    51. Kennedy MP, Jimenez CA, Chang J, Fossella F, Eapen GA, Morice RC. Optimisation of bronchial brachytherapy catheter placement with a modified airway stent. Eur Respir J. 2008 Apr; 31(4):902-3. PMID: 18378785.
      Citations:    Fields:    Translation:Humans
    52. Kalemkerian GP, Akerley W, Downey RJ, Ettinger DS, Fossella F, Grecula JC, Jahan T, Johnson BE, Kessinger A, Koczywas M, Langer CJ, Martins R, Niell HB, Pan CC, Ramnath N, Ready N, Robert F, Williams CC. Small cell lung cancer. J Natl Compr Canc Netw. 2008 Mar; 6(3):294-314. PMID: 18377848.
      Citations: 1     Fields:    Translation:Humans
    53. de Marinis F, Pereira JR, Fossella F, Perry MC, Reck M, Salzberg M, Jassem J, Peterson P, Liepa AM, Moore P, Gralla RJ. Lung Cancer Symptom Scale outcomes in relation to standard efficacy measures: an analysis of the phase III study of pemetrexed versus docetaxel in advanced non-small cell lung cancer. J Thorac Oncol. 2008 Jan; 3(1):30-6. PMID: 18166838.
      Citations: 17     Fields:    Translation:Humans
    54. Douillard JY, Laporte S, Fossella F, Georgoulias V, Pujol JL, Kubota K, Monnier A, Kudoh S, Rubio JE, Cucherat M. Comparison of docetaxel- and vinca alkaloid-based chemotherapy in the first-line treatment of advanced non-small cell lung cancer: a meta-analysis of seven randomized clinical trials. J Thorac Oncol. 2007 Oct; 2(10):939-46. PMID: 17909357.
      Citations: 15     Fields:    Translation:Humans
    55. Ardizzoni A, Boni L, Tiseo M, Fossella FV, Schiller JH, Paesmans M, Radosavljevic D, Paccagnella A, Zatloukal P, Mazzanti P, Bisset D, Rosell R, CISCA (CISplatin versus CArboplatin) Meta-analysis Group. Cisplatin- versus carboplatin-based chemotherapy in first-line treatment of advanced non-small-cell lung cancer: an individual patient data meta-analysis. J Natl Cancer Inst. 2007 Jun 06; 99(11):847-57. PMID: 17551145.
      Citations: 177     Fields:    Translation:Humans
    56. Huang EH, Liao Z, Cox JD, Guerrero TM, Chang JY, Jeter M, Borghero Y, Wei X, Fossella F, Herbst RS, Blumenschein GR, Moran C, Allen PK, Komaki R. Comparison of outcomes for patients with unresectable, locally advanced non-small-cell lung cancer treated with induction chemotherapy followed by concurrent chemoradiation vs. concurrent chemoradiation alone. Int J Radiat Oncol Biol Phys. 2007 Jul 01; 68(3):779-85. PMID: 17418967.
      Citations: 3     Fields:    Translation:Humans
    57. Weiss GJ, Rosell R, Fossella F, Perry M, Stahel R, Barata F, Nguyen B, Paul S, McAndrews P, Hanna N, Kelly K, Bunn PA. The impact of induction chemotherapy on the outcome of second-line therapy with pemetrexed or docetaxel in patients with advanced non-small-cell lung cancer. Ann Oncol. 2007 Mar; 18(3):453-60. PMID: 17322539.
      Citations: 16     Fields:    Translation:HumansCTClinical Trials
    58. Altundag O, Stewart DJ, Fossella FV, Ayers GD, Wei W, Zhou X, Zinner RG. Many patients 80 years and older with advanced non-small cell lung cancer (NSCLC) can tolerate chemotherapy. J Thorac Oncol. 2007 Feb; 2(2):141-6. PMID: 17410030.
      Citations: 13     Fields:    Translation:Humans
    59. Fanucchi MP, Fossella FV, Belt R, Natale R, Fidias P, Carbone DP, Govindan R, Raez LE, Robert F, Ribeiro M, Akerley W, Kelly K, Limentani SA, Crawford J, Reimers HJ, Axelrod R, Kashala O, Sheng S, Schiller JH. Randomized phase II study of bortezomib alone and bortezomib in combination with docetaxel in previously treated advanced non-small-cell lung cancer. J Clin Oncol. 2006 Nov 01; 24(31):5025-33. PMID: 17075122.
      Citations: 65     Fields:    Translation:HumansCTClinical Trials
    60. Johnson BE, Crawford J, Downey RJ, Ettinger DS, Fossella F, Grecula JC, Jahan T, Kalemkerian GP, Kessinger A, Koczywas M, Langer CJ, Martins R, Marymont MH, Niell HB, Ramnath N, Robert F, Williams CC, National Comprehensive Cancer Network (NCCN). Small cell lung cancer clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2006 Jul; 4(6):602-22. PMID: 16813728.
      Citations: 14     Fields:    Translation:Humans
    61. Belani CP, Pereira JR, von Pawel J, Pluzanska A, Gorbounova V, Kaukel E, Mattson KV, Ramlau R, Szczesna A, Fidias P, Millward M, Fossella F, TAX 326 study group. Effect of chemotherapy for advanced non-small cell lung cancer on patients' quality of life. A randomized controlled trial. Lung Cancer. 2006 Aug; 53(2):231-9. PMID: 16787687.
      Citations: 19     Fields:    Translation:Humans
    62. Montoya M, Fossella F, Palmer JL, Kaur G, Pace EA, Yadav R, Simmonds M, Gillis T, Bruera E. Objective evaluation of physical function in patients with advanced lung cancer: a preliminary report. J Palliat Med. 2006 Apr; 9(2):309-16. PMID: 16629561.
      Citations: 4     Fields:    Translation:Humans
    63. Thomas SK, Fossella FV, Liu D, Schaerer R, Tsao AS, Kies MS, Pisters KM, Blumenschein GR, Glisson BS, Lee JJ, Herbst RS, Zinner RG. Asian ethnicity as a predictor of response in patients with non-small-cell lung cancer treated with gefitinib on an expanded access program. Clin Lung Cancer. 2006 Mar; 7(5):326-31. PMID: 16640804.
      Citations: 8     Fields:    Translation:Humans
    64. Belani CP, Fossella F. Elderly subgroup analysis of a randomized phase III study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for first-line treatment of advanced nonsmall cell lung carcinoma (TAX 326). Cancer. 2005 Dec 15; 104(12):2766-74. PMID: 16288485.
      Citations: 32     Fields:    Translation:HumansCTClinical Trials
    65. Zinner RG, Fossella FV, Gladish GW, Glisson BS, Blumenschein GR, Papadimitrakopoulou VA, Pisters KM, Kim ES, Oh YW, Peeples BO, Ye Z, Curiel RE, Obasaju CK, Hong WK, Herbst RS. Phase II study of pemetrexed in combination with carboplatin in the first-line treatment of advanced nonsmall cell lung cancer. Cancer. 2005 Dec 01; 104(11):2449-56. PMID: 16258975.
      Citations: 21     Fields:    Translation:HumansCTClinical Trials
    66. Robert F, Blumenschein G, Herbst RS, Fossella FV, Tseng J, Saleh MN, Needle M. Phase I/IIa study of cetuximab with gemcitabine plus carboplatin in patients with chemotherapy-naive advanced non-small-cell lung cancer. J Clin Oncol. 2005 Dec 20; 23(36):9089-96. PMID: 16301597.
      Citations: 33     Fields:    Translation:HumansCTClinical Trials
    67. Kim ES, Kies MS, Fossella FV, Glisson BS, Zaknoen S, Statkevich P, Munden RF, Summey C, Pisters KM, Papadimitrakopoulou V, Tighiouart M, Rogatko A, Khuri FR. Phase II study of the farnesyltransferase inhibitor lonafarnib with paclitaxel in patients with taxane-refractory/resistant nonsmall cell lung carcinoma. Cancer. 2005 Aug 01; 104(3):561-9. PMID: 16028213.
      Citations: 28     Fields:    Translation:HumansCTClinical Trials
    68. Liao Z, Komaki R, Milas L, Yuan C, Kies M, Chang JY, Jeter M, Guerrero T, Blumenschien G, Smith CM, Fossella F, Brown B, Cox JD. A phase I clinical trial of thoracic radiotherapy and concurrent celecoxib for patients with unfavorable performance status inoperable/unresectable non-small cell lung cancer. Clin Cancer Res. 2005 May 01; 11(9):3342-8. PMID: 15867233.
      Citations: 16     Fields:    Translation:HumansCTClinical Trials
    69. Chang JY, Komaki R, Sasaki R, Liao Z, Stevens CW, Lu C, Fossella FV, Allen PK, Cox JD, Spitz MR, Wu X. High mutagen sensitivity in peripheral blood lymphocytes predicts poor overall and disease-specific survival in patients with stage III non-small cell lung cancer treated with radiotherapy and chemotherapy. Clin Cancer Res. 2005 Apr 15; 11(8):2894-8. PMID: 15837739.
      Citations: 1     Fields:    Translation:HumansCells
    70. Komaki R, Chang JY, Wu X, Allen PK, Milas L, Liao Z, Fossella FV, Travis E, Spitz MR. Mutagen sensitivity may predict lung protection by amifostine for patients with locally advanced non-small cell lung cancer treated by chemoradiotherapy. Semin Oncol. 2005 Apr; 32(2 Suppl 3):S92-8. PMID: 16015542.
      Citations:    Fields:    Translation:HumansPHPublic HealthCTClinical Trials
    71. Montero A, Fossella F, Hortobagyi G, Valero V. Docetaxel for treatment of solid tumours: a systematic review of clinical data. Lancet Oncol. 2005 Apr; 6(4):229-39. PMID: 15811618.
      Citations: 87     Fields:    Translation:Humans
    72. Zinner RG, Fossella FV, Herbst RS. Pemetrexed in advanced NSCLC: a review of the clinical data. Oncology (Williston Park). 2004 Jul; 18(8 Suppl 5):54-62. PMID: 15339061.
      Citations: 2     Fields:    Translation:Humans
    73. Tran HT, Blumenschein GR, Lu C, Meyers CA, Papadimitrakopoulou V, Fossella FV, Zinner R, Madden T, Smythe LG, Puduvalli VK, Munden R, Truong M, Herbst RS. Clinical and pharmacokinetic study of TNP-470, an angiogenesis inhibitor, in combination with paclitaxel and carboplatin in patients with solid tumors. Cancer Chemother Pharmacol. 2004 Oct; 54(4):308-14. PMID: 15184994.
      Citations: 10     Fields:    Translation:HumansCTClinical Trials
    74. Kim ES, Putnam JB, Komaki R, Walsh GL, Ro JY, Shin HJ, Truong M, Moon H, Swisher SG, Fossella FV, Khuri FR, Hong WK, Shin DM. Phase II study of a multidisciplinary approach with induction chemotherapy, followed by surgical resection, radiation therapy, and consolidation chemotherapy for unresectable malignant thymomas: final report. Lung Cancer. 2004 Jun; 44(3):369-79. PMID: 15140551.
      Citations: 70     Fields:    Translation:HumansCTClinical Trials
    75. Hanna N, Shepherd FA, Fossella FV, Pereira JR, De Marinis F, von Pawel J, Gatzemeier U, Tsao TC, Pless M, Muller T, Lim HL, Desch C, Szondy K, Gervais R, Manegold C, Paul S, Paoletti P, Einhorn L, Bunn PA. Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. J Clin Oncol. 2004 May 01; 22(9):1589-97. PMID: 15117980.
      Citations: 709     Fields:    Translation:HumansCTClinical Trials
    76. Khuri FR, Glisson BS, Kim ES, Statkevich P, Thall PF, Meyers ML, Herbst RS, Munden RF, Tendler C, Zhu Y, Bangert S, Thompson E, Lu C, Wang XM, Shin DM, Kies MS, Papadimitrakopoulou V, Fossella FV, Kirschmeier P, Bishop WR, Hong WK. Phase I study of the farnesyltransferase inhibitor lonafarnib with paclitaxel in solid tumors. Clin Cancer Res. 2004 May 01; 10(9):2968-76. PMID: 15131032.
      Citations: 19     Fields:    Translation:HumansCTClinical Trials
    77. Komaki R, Lee JS, Milas L, Lee HK, Fossella FV, Herbst RS, Allen PK, Liao Z, Stevens CW, Lu C, Zinner RG, Papadimitrakopoulou VA, Kies MS, Blumenschein GR, Pisters KM, Glisson BS, Kurie J, Kaplan B, Garza VP, Mooring D, Tucker SL, Cox JD. Effects of amifostine on acute toxicity from concurrent chemotherapy and radiotherapy for inoperable non-small-cell lung cancer: report of a randomized comparative trial. Int J Radiat Oncol Biol Phys. 2004 Apr 01; 58(5):1369-77. PMID: 15050312.
      Citations: 26     Fields:    Translation:HumansCTClinical Trials
    78. Zinner RG, Glisson BS, Fossella FV, Pisters KM, Kies MS, Lee PM, Massarelli E, Sabloff B, Fritsche HA, Ro JY, Ordonez NG, Tran HT, Yang Y, Smith TL, Mass RD, Herbst RS. Trastuzumab in combination with cisplatin and gemcitabine in patients with Her2-overexpressing, untreated, advanced non-small cell lung cancer: report of a phase II trial and findings regarding optimal identification of patients with Her2-overexpressing disease. Lung Cancer. 2004 Apr; 44(1):99-110. PMID: 15013588.
      Citations: 33     Fields:    Translation:HumansCellsCTClinical Trials
    79. Fossella FV. Pemetrexed for treatment of advanced non-small cell lung cancer. Semin Oncol. 2004 Feb; 31(1 Suppl 1):100-5. PMID: 14981587.
      Citations: 1     Fields:    Translation:Humans
    80. Murray N, Salgia R, Fossella FV. Targeted molecules in small cell lung cancer. Semin Oncol. 2004 Feb; 31(1 Suppl 1):106-11. PMID: 14981588.
      Citations: 8     Fields:    Translation:Humans
    81. Taylor NA, Liao ZX, Cox JD, Stevens C, Roth J, Walsh G, Chang JY, Guerrero T, Jeter M, Putnam J, Fossella FV, Allen P, Komaki R. Equivalent outcome of patients with clinical Stage IIIA non-small-cell lung cancer treated with concurrent chemoradiation compared with induction chemotherapy followed by surgical resection. Int J Radiat Oncol Biol Phys. 2004 Jan 01; 58(1):204-12. PMID: 14697440.
      Citations: 13     Fields:    Translation:Humans
    82. Fossella F, Pereira JR, von Pawel J, Pluzanska A, Gorbounova V, Kaukel E, Mattson KV, Ramlau R, Szczesna A, Fidias P, Millward M, Belani CP. Randomized, multinational, phase III study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for advanced non-small-cell lung cancer: the TAX 326 study group. J Clin Oncol. 2003 Aug 15; 21(16):3016-24. PMID: 12837811.
      Citations: 244     Fields:    Translation:HumansCTClinical Trials
    83. Johnson FM, Kurie JM, Peeples BO, Lee JJ, Feng L, Pisters KM, Fossella FV, Papadimitrakopoulou VA, Blumenschein GR, Komaki R, Glisson BS. Phase I study of weekly alternating therapy with irinotecan/cisplatin and etoposide/cisplatin for patients with small-cell lung cancer. Clin Lung Cancer. 2003 Jul; 5(1):40-5. PMID: 14596703.
      Citations:    Fields:    Translation:HumansCTClinical Trials
    84. Taylor NA, Liao ZX, Stevens C, Walsh G, Roth J, Putnam J, Fossella F, Allen P, Cox JD, Komaki R. Postoperative radiotherapy increases locoregional control of patients with stage IIIA non-small-cell lung cancer treated with induction chemotherapy followed by surgery. Int J Radiat Oncol Biol Phys. 2003 Jul 01; 56(3):616-25. PMID: 12788166.
      Citations: 4     Fields:    Translation:Humans
    85. Johnson FM, Kurie JM, Peeples BO, Pisters KM, Fossella FV, Papadimitrakopoulou VA, Blumenschein GR, Komaki R, Glisson BS. Dose-dense therapy with a novel irinotecan regimen for small-cell lung cancer. Oncology (Williston Park). 2003 Jul; 17(7 Suppl 7):17-21. PMID: 12886869.
      Citations:    Fields:    Translation:HumansCTClinical Trials
    86. Lu C, Komaki R, Lee JS, Shin DM, Palmer JL, Coldman BJ, Pisters KM, Kurie JM, Fossella FV, Glisson BS. A phase I study of topotecan/paclitaxel alternating with etoposide/cisplatin and thoracic irradiation in patients with limited small cell lung cancer. Clin Cancer Res. 2003 Jun; 9(6):2085-91. PMID: 12796372.
      Citations: 1     Fields:    Translation:HumansCTClinical Trials
    87. Swisher SG, Roth JA, Komaki R, Gu J, Lee JJ, Hicks M, Ro JY, Hong WK, Merritt JA, Ahrar K, Atkinson NE, Correa AM, Dolormente M, Dreiling L, El-Naggar AK, Fossella F, Francisco R, Glisson B, Grammer S, Herbst R, Huaringa A, Kemp B, Khuri FR, Kurie JM, Liao Z, McDonnell TJ, Morice R, Morello F, Munden R, Papadimitrakopoulou V, Pisters KM, Putnam JB, Sarabia AJ, Shelton T, Stevens C, Shin DM, Smythe WR, Vaporciyan AA, Walsh GL, Yin M. Induction of p53-regulated genes and tumor regression in lung cancer patients after intratumoral delivery of adenoviral p53 (INGN 201) and radiation therapy. Clin Cancer Res. 2003 Jan; 9(1):93-101. PMID: 12538456.
      Citations: 48     Fields:    Translation:HumansCellsCTClinical Trials
    88. Massarelli E, Andre F, Liu DD, Lee JJ, Wolf M, Fandi A, Ochs J, Le Chevalier T, Fossella F, Herbst RS. A retrospective analysis of the outcome of patients who have received two prior chemotherapy regimens including platinum and docetaxel for recurrent non-small-cell lung cancer. Lung Cancer. 2003 Jan; 39(1):55-61. PMID: 12499095.
      Citations: 49     Fields:    Translation:Humans
    89. Fossella FV, Lynch T, Shepherd FA. Second line chemotherapy for NSCLC: establishing a gold standard. Lung Cancer. 2002 Dec; 38 Suppl 4:5-12. PMID: 12480189.
      Citations: 5     Fields:    Translation:Humans
    90. Rosell R, Fossella F, Milas L, Spanish Lung Cancer Group. Molecular markers and targeted therapy with novel agents: prospects in the treatment of non-small cell lung cancer. Lung Cancer. 2002 Dec; 38 Suppl 4:43-9. PMID: 12480194.
      Citations: 6     Fields:    Translation:HumansCells
    91. Herbst RS, Madden TL, Tran HT, Blumenschein GR, Meyers CA, Seabrooke LF, Khuri FR, Puduvalli VK, Allgood V, Fritsche HA, Hinton L, Newman RA, Crane EA, Fossella FV, Dordal M, Goodin T, Hong WK. Safety and pharmacokinetic effects of TNP-470, an angiogenesis inhibitor, combined with paclitaxel in patients with solid tumors: evidence for activity in non-small-cell lung cancer. J Clin Oncol. 2002 Nov 15; 20(22):4440-7. PMID: 12431966.
      Citations: 24     Fields:    Translation:HumansCTClinical Trials
    92. Herbst RS, Khuri FR, Lu C, Liu DD, Fossella FV, Glisson BS, Pisters KM, Shin DM, Papadimitrakopoulou VA, Kurie JM, Blumenschein G, Kies MS, Zinner R, Jung MS, Lu R, Lee JJ, Munden RF, Hong WK, Lee JS. The novel and effective nonplatinum, nontaxane combination of gemcitabine and vinorelbine in advanced nonsmall cell lung carcinoma: potential for decreased toxicity and combination with biological therapy. Cancer. 2002 Jul 15; 95(2):340-53. PMID: 12124835.
      Citations: 7     Fields:    Translation:HumansCTClinical Trials
    93. Liao Z, Komaki R, Stevens C, Kelly J, Fossella F, Lee JS, Allen P, Cox JD. Twice daily irradiation increases locoregional control in patients with medically inoperable or surgically unresectable stage II-IIIB non-small-cell lung cancer. Int J Radiat Oncol Biol Phys. 2002 Jul 01; 53(3):558-65. PMID: 12062597.
      Citations: 1     Fields:    Translation:Humans
    94. Fossella FV. Docetaxel for previously treated non-small-cell lung cancer. Oncology (Williston Park). 2002 Jun; 16(6 Suppl 6):45-51. PMID: 12108897.
      Citations: 12     Fields:    Translation:Humans
    95. Fossella FV. Docetaxel in second-line treatment of non-small-cell lung cancer. Clin Lung Cancer. 2002 May; 3 Suppl 2:S23-8. PMID: 14720344.
      Citations: 6     Fields:    
    96. Fossella FV, Gatzemeier U. Phase I trials of pemetrexed. Semin Oncol. 2002 Apr; 29(2 Suppl 5):8-16. PMID: 12023787.
      Citations: 5     Fields:    Translation:Humans
    97. Komaki R, Lee JS, Kaplan B, Allen P, Kelly JF, Liao Z, Stevens CW, Fossella FV, Zinner R, Papadimitrakopoulou V, Khuri F, Glisson B, Pisters K, Kurie J, Herbst R, Milas L, Ro J, Thames HD, Hong WK, Cox JD. Randomized phase III study of chemoradiation with or without amifostine for patients with favorable performance status inoperable stage II-III non-small cell lung cancer: preliminary results. Semin Radiat Oncol. 2002 Jan; 12(1 Suppl 1):46-9. PMID: 11917284.
      Citations: 14     Fields:    Translation:HumansPHPublic HealthCTClinical Trials
    98. Komaki R, Chasen MH, Travis WD, Putnam JB, Fossella FV, Byhardt RW, Ro JY. Oncodiagnosis panel: 1999. Cancer of the lung: oncodiagnosis. Radiographics. 2001 Nov-Dec; 21(6):1573-96. PMID: 11706227.
      Citations:    Fields:    Translation:Humans
    99. Herbst RS, Khuri FR, Fossella FV, Glisson BS, Kies MS, Pisters KM, Riddle JR, Terry KA, Lee JS. ZD1839 (Iressa) in non-small-cell lung cancer. Clin Lung Cancer. 2001 Aug; 3(1):27-32. PMID: 14656386.
      Citations:    Fields:    
    100. Khuri FR, Herbst RS, Fossella FV. Emerging therapies in non-small-cell lung cancer. Ann Oncol. 2001 Jun; 12(6):739-44. PMID: 11484947.
      Citations: 13     Fields:    Translation:Humans
    101. Shepherd FA, Fossella FV, Lynch T, Armand JP, Rigas JR, Kris MG. Docetaxel (Taxotere) shows survival and quality-of-life benefits in the second-line treatment of non-small cell lung cancer: a review of two phase III trials. Semin Oncol. 2001 Feb; 28(1 Suppl 2):4-9. PMID: 11284623.
      Citations: 7     Fields:    Translation:Humans
    102. Shepherd FA, Fossella FV, Lynch T, Armand JP, Rigas JR, Kris MG. Docetaxel (Taxotere) shows survival and quality-of-life benefits in the second-line treatment of non-small cell lung cancer: A review of two phase III trials. Semin Oncol. 2001 Feb; 28 Suppl 2:4-9. PMID: 28140080.
      Citations:    Fields:    
    103. Perez-Cardona JH, Ordonez NG, Fossella FV. Lymph node micrometastases in non small-cell lung cancer: clinical applications. Clin Lung Cancer. 2000 Nov; 2(2):116-20. PMID: 14731321.
      Citations: 1     Fields:    
    104. Komaki R, Roth JA, Walsh GL, Putnam JB, Vaporciyan A, Lee JS, Fossella FV, Chasen M, Delclos ME, Cox JD. Outcome predictors for 143 patients with superior sulcus tumors treated by multidisciplinary approach at the University of Texas M. D. Anderson Cancer Center. Int J Radiat Oncol Biol Phys. 2000 Sep 01; 48(2):347-54. PMID: 10974447.
      Citations: 5     Fields:    Translation:Humans
    105. Oh Y, Perez-Soler R, Fossella FV, Glisson BS, Kurie J, Walsh GL, Truong M, Shin DM. Phase II study of intravenous Doxil in malignant pleural mesothelioma. Invest New Drugs. 2000 Aug; 18(3):243-5. PMID: 10958592.
      Citations: 4     Fields:    Translation:HumansCTClinical Trials
    106. Fossella FV, DeVore R, Kerr RN, Crawford J, Natale RR, Dunphy F, Kalman L, Miller V, Lee JS, Moore M, Gandara D, Karp D, Vokes E, Kris M, Kim Y, Gamza F, Hammershaimb L. Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens. The TAX 320 Non-Small Cell Lung Cancer Study Group. J Clin Oncol. 2000 Jun; 18(12):2354-62. PMID: 10856094.
      Citations: 330     Fields:    Translation:HumansCTClinical Trials
    107. Liu NS, Spitz MR, Kemp BL, Cooksley C, Fossella FV, Lee JS, Hong WK, Khuri FR. Adenocarcinoma of the lung in young patients: the M. D. Anderson experience. Cancer. 2000 Apr 15; 88(8):1837-41. PMID: 10760760.
      Citations: 24     Fields:    Translation:Humans
    108. Nemunaitis J, Swisher SG, Timmons T, Connors D, Mack M, Doerksen L, Weill D, Wait J, Lawrence DD, Kemp BL, Fossella F, Glisson BS, Hong WK, Khuri FR, Kurie JM, Lee JJ, Lee JJ, Lee JS, Nguyen DM, Nesbitt JC, Perez-Soler R, Pisters KM, Putnam JB, Richli WR, Shin DM, Walsh GL, Merritt J, Roth J. Adenovirus-mediated p53 gene transfer in sequence with cisplatin to tumors of patients with non-small-cell lung cancer. J Clin Oncol. 2000 Feb; 18(3):609-22. PMID: 10653876.
      Citations: 44     Fields:    Translation:HumansCellsCTClinical Trials
    109. Fossella FV. Second-line chemotherapy for non-small-cell lung cancer. Curr Oncol Rep. 2000 Jan; 2(1):96-101. PMID: 11122830.
      Citations: 4     Fields:    Translation:Humans
    110. Fossella F, Rigas JR, Belani CP. New options in the treatment of non-small cell lung cancer. Anticancer Drugs. 1999 Nov; 10 Suppl 1:S25-8. PMID: 10630365.
      Citations:    Fields:    Translation:Humans
    111. Fossella FV. Docetaxel in the treatment of non-small cell lung cancer: review of single-agent trials. Semin Oncol. 1999 Oct; 26(5 Suppl 16):17-23; discussion 41-2. PMID: 10585004.
      Citations: 6     Fields:    Translation:Humans
    112. Glisson BS, Kurie JM, Perez-Soler R, Fox NJ, Murphy WK, Fossella FV, Lee JS, Ross MB, Nyberg DA, Pisters KM, Shin DM, Hong WK. Cisplatin, etoposide, and paclitaxel in the treatment of patients with extensive small-cell lung carcinoma. J Clin Oncol. 1999 Aug; 17(8):2309-15. PMID: 10561292.
      Citations: 8     Fields:    Translation:HumansCTClinical Trials
    113. Fossella FV, Rigas J. The use of docetaxel (Taxotere) in patients with advanced non-small cell lung cancer previously treated with platinum-containing chemotherapy regimens. Semin Oncol. 1999 Jun; 26(3 Suppl 11):9-12. PMID: 10458204.
      Citations: 3     Fields:    Translation:HumansCTClinical Trials
    114. Fossella FV. Overview of docetaxel (Taxotere) in the treatment of non-small cell lung cancer. Semin Oncol. 1999 Jun; 26(3 Suppl 11):4-8. PMID: 10458203.
      Citations: 1     Fields:    Translation:Humans
    115. Swisher SG, Roth JA, Nemunaitis J, Lawrence DD, Kemp BL, Carrasco CH, Connors DG, El-Naggar AK, Fossella F, Glisson BS, Hong WK, Khuri FR, Kurie JM, Lee JJ, Lee JS, Mack M, Merritt JA, Nguyen DM, Nesbitt JC, Perez-Soler R, Pisters KM, Putnam JB, Richli WR, Savin M, Schrump DS, Shin DM, Shulkin A, Walsh GL, Wait J, Weill D, Waugh MK. Adenovirus-mediated p53 gene transfer in advanced non-small-cell lung cancer. J Natl Cancer Inst. 1999 May 05; 91(9):763-71. PMID: 10328106.
      Citations: 56     Fields:    Translation:HumansCellsCTClinical Trials
    116. Lee JS, Komaki R, Fossella FV, Glisson BS, Hong WK, Cox JD. A pilot trial of hyperfractionated thoracic radiation therapy with concurrent cisplatin and oral etoposide for locally advanced inoperable non-small-cell lung cancer: a 5-year follow-up report. Int J Radiat Oncol Biol Phys. 1998 Oct 01; 42(3):479-86. PMID: 9806504.
      Citations: 4     Fields:    Translation:Humans
    117. Roth JA, Atkinson EN, Fossella F, Komaki R, Bernadette Ryan M, Putnam JB, Lee JS, Dhingra H, De Caro L, Chasen M, Hong WK. Long-term follow-up of patients enrolled in a randomized trial comparing perioperative chemotherapy and surgery with surgery alone in resectable stage IIIA non-small-cell lung cancer. Lung Cancer. 1998 Jul; 21(1):1-6. PMID: 9792048.
      Citations: 71     Fields:    Translation:HumansCTClinical Trials
    118. Roth JA, Swisher SG, Merritt JA, Lawrence DD, Kemp BL, Carrasco CH, El-Naggar AK, Fossella FV, Glisson BS, Hong WK, Khurl FR, Kurie JM, Nesbitt JC, Pisters K, Putnam JB, Schrump DS, Shin DM, Walsh GL. Gene therapy for non-small cell lung cancer: a preliminary report of a phase I trial of adenoviral p53 gene replacement. Semin Oncol. 1998 Jun; 25(3 Suppl 8):33-7. PMID: 9704675.
      Citations: 11     Fields:    Translation:HumansCellsCTClinical Trials
    119. Khuri FR, Fossella FV, Lee JS, Murphy WK, Shin DM, Markowitz AB, Glisson BS. Phase II trial of recombinant IFN-alpha2a with etoposide/cisplatin induction and interferon/megestrol acetate maintenance in extensive small cell lung cancer. J Interferon Cytokine Res. 1998 Apr; 18(4):241-5. PMID: 9568726.
      Citations:    Fields:    Translation:HumansCTClinical Trials
    120. Glisson B, Lee JS, Palmer J, Fossella F, Shin DM, Murphy WK, Perez-Soler R, Hong WK. Cisplatin, ifosfamide, and prolonged oral etoposide in the treatment of patients with extensive small cell lung carcinoma. Cancer. 1998 Jan 15; 82(2):301-8. PMID: 9445186.
      Citations: 3     Fields:    Translation:HumansCellsCTClinical Trials
    121. Glisson B, Komaki R, Lee JS, Shin DM, Fossella F, Murphy WK, Kurie J, Perez-Soler R, Schea R, Vadhan-Raj S. Integration of filgrastim into chemoradiation for limited small cell lung cancer: a Phase I study. Int J Radiat Oncol Biol Phys. 1998 Jan 15; 40(2):331-6. PMID: 9457817.
      Citations: 1     Fields:    Translation:HumansCTClinical Trials
    122. Hille D, Riva A, Vivier N, ten Bokkel Huinnink WW, van Oosterom AT, Kaye SB, Verweij J, Fossella FV, Valero V, Rigas JR, Seidman AD, Chevallier B, Fumoleau P, Burris HA, Ravdin PM, Sheiner LB, Bruno R. Population pharmacokinetics/pharmacodynamics of docetaxel in phase II studies in patients with cancer. J Clin Oncol. 1998 Jan; 16(1):187-96. PMID: 9440742.
      Citations: 119     Fields:    Translation:HumansCTClinical Trials
    123. Shade RJ, Pisters KM, Huber MH, Fossella F, Perez-Soler R, Shin DM, Kurie J, Glisson B, Lippman S, Lee JS. Phase I study of paclitaxel administered by ten-day continuous infusion. Invest New Drugs. 1998-1999; 16(3):237-43. PMID: 10360603.
      Citations: 2     Fields:    Translation:HumansCTClinical Trials
    124. Haskell CM, Mendoza E, Pisters KM, Fossella FV, Figlin RA. Phase II study of intravenous adenosine 5'-triphosphate in patients with previously untreated stage IIIB and stage IV non-small cell lung cancer. Invest New Drugs. 1998; 16(1):81-5. PMID: 9740548.
      Citations: 14     Fields:    Translation:HumansCTClinical Trials
    125. Fossella FV, Lee JS, Hong WK. Management strategies for recurrent non-small cell lung cancer. Semin Oncol. 1997 Aug; 24(4):455-62. PMID: 9280225.
      Citations: 9     Fields:    Translation:Humans
    126. Lee JS, Pisters KM, Komaki R, Glisson BS, Khuri FR, Schea R, Fossella FV. Paclitaxel/carboplatin chemotherapy as primary treatment of brain metastases in non-small cell lung cancer: a preliminary report. Semin Oncol. 1997 Aug; 24(4 Suppl 12):S12-52-S12-55. PMID: 9331122.
      Citations: 6     Fields:    Translation:HumansCTClinical Trials
    127. Komaki R, Scott C, Ettinger D, Lee JS, Fossella FV, Curran W, Evans RF, Rubin P, Byhardt RW. Randomized study of chemotherapy/radiation therapy combinations for favorable patients with locally advanced inoperable nonsmall cell lung cancer: Radiation Therapy Oncology Group (RTOG) 92-04. Int J Radiat Oncol Biol Phys. 1997 Apr 01; 38(1):149-55. PMID: 9212017.
      Citations: 11     Fields:    Translation:HumansCTClinical Trials
    128. Fossella FV, Lippman SM, Shin DM, Tarassoff P, Calayag-Jung M, Perez-Soler R, Lee JS, Murphy WK, Glisson B, Rivera E, Hong WK. Maximum-tolerated dose defined for single-agent gemcitabine: a phase I dose-escalation study in chemotherapy-naive patients with advanced non-small-cell lung cancer. J Clin Oncol. 1997 Jan; 15(1):310-6. PMID: 8996158.
      Citations: 19     Fields:    Translation:HumansCTClinical Trials
    129. Demetri G, Elias A, Gershenson D, Fossella F, Grecula J, Mittal B, Raschko J, Robertson J. NCCN Small-Cell Lung Cancer Practice Guidelines. The National Comprehensive Cancer Network. Oncology (Williston Park). 1996 Nov; 10(11 Suppl):179-94. PMID: 8953602.
      Citations: 5     Fields:    Translation:Humans
    130. Perez-Soler R, Glisson BS, Lee JS, Fossella FV, Murphy WK, Shin DM, Hong WK. Treatment of patients with small-cell lung cancer refractory to etoposide and cisplatin with the topoisomerase I poison topotecan. J Clin Oncol. 1996 Oct; 14(10):2785-90. PMID: 8874340.
      Citations: 20     Fields:    Translation:Humans
    131. Lee JS, Scott C, Komaki R, Fossella FV, Dundas GS, McDonald S, Byhardt RW, Curran WJ. Concurrent chemoradiation therapy with oral etoposide and cisplatin for locally advanced inoperable non-small-cell lung cancer: radiation therapy oncology group protocol 91-06. J Clin Oncol. 1996 Apr; 14(4):1055-64. PMID: 8648357.
      Citations: 22     Fields:    Translation:HumansCTClinical Trials
    132. Fossella FV, Rivera E, Roth JA. Preoperative chemotherapy for stage IIIa non-small cell lung cancer. Curr Opin Oncol. 1996 Mar; 8(2):106-11. PMID: 8727302.
      Citations:    Fields:    Translation:Humans
    133. Perez-Soler R, Fossella FV, Glisson BS, Lee JS, Murphy WK, Shin DM, Kemp BL, Lee JJ, Kane J, Robinson RA, Lippman SM, Kurie JM, Huber MH, Raber MN, Hong WK. Phase II study of topotecan in patients with advanced non-small-cell lung cancer previously untreated with chemotherapy. J Clin Oncol. 1996 Feb; 14(2):503-13. PMID: 8636764.
      Citations: 16     Fields:    Translation:HumansCTClinical Trials
    134. Huber MH, Lee JS, Newman RA, Fossella FV, Wester M, Hong WK, Lippman SM. A phase I investigation of the sequential use of methotrexate and paclitaxel with and without G-CSF for the treatment of solid tumors. Ann Oncol. 1996 Jan; 7(1):59-63. PMID: 9081393.
      Citations: 1     Fields:    Translation:HumansCTClinical Trials
    135. Shin DM, Fossella FV, Umsawasdi T, Murphy WK, Chasen MH, Walsh G, Komaki R, McMurtrey MJ, Hong WK. Prospective study of combination chemotherapy with cyclophosphamide, doxorubicin, and cisplatin for unresectable or metastatic malignant pleural mesothelioma. Cancer. 1995 Dec 01; 76(11):2230-6. PMID: 8635025.
      Citations: 6     Fields:    Translation:HumansCTClinical Trials
    136. Lee JS, Newman RA, Lippman SM, Fossella FV, Calayag M, Raber MN, Krakoff IH, Hong WK. Phase I evaluation of all-trans retinoic acid with and without ketoconazole in adults with solid tumors. J Clin Oncol. 1995 Jun; 13(6):1501-8. PMID: 7751898.
      Citations: 10     Fields:    Translation:HumansCTClinical Trials
    137. Fossella FV, Lee JS, Berille J, Hong WK. Summary of phase II data of docetaxel (Taxotere), an active agent in the first- and second-line treatment of advanced non-small cell lung cancer. Semin Oncol. 1995 Apr; 22(2 Suppl 4):22-9. PMID: 7740327.
      Citations: 7     Fields:    Translation:Humans
    138. Fossella FV, Lee JS, Shin DM, Calayag M, Huber M, Perez-Soler R, Murphy WK, Lippman S, Benner S, Glisson B, et al. Phase II study of docetaxel for advanced or metastatic platinum-refractory non-small-cell lung cancer. J Clin Oncol. 1995 Mar; 13(3):645-51. PMID: 7884425.
      Citations: 36     Fields:    Translation:HumansCTClinical Trials
    139. Komaki R, Shin DM, Glisson BS, Fossella FV, Murphy WK, Garden AS, Oswald MJ, Hong WK, Roth JA, Peters LJ, et al. Interdigitating versus concurrent chemotherapy and radiotherapy for limited small cell lung cancer. Int J Radiat Oncol Biol Phys. 1995 Feb 15; 31(4):807-11. PMID: 7860392.
      Citations:    Fields:    Translation:HumansCTClinical Trials
    140. Fossella FV, Lee JS, Murphy WK, Lippman SM, Calayag M, Pang A, Chasen M, Shin DM, Glisson B, Benner S, et al. Phase II study of docetaxel for recurrent or metastatic non-small-cell lung cancer. J Clin Oncol. 1994 Jun; 12(6):1238-44. PMID: 7911160.
      Citations: 35     Fields:    Translation:HumansCTClinical Trials
    141. Roth JA, Fossella F, Komaki R, Ryan MB, Putnam JB, Lee JS, Dhingra H, De Caro L, Chasen M, McGavran M, et al. A randomized trial comparing perioperative chemotherapy and surgery with surgery alone in resectable stage IIIA non-small-cell lung cancer. J Natl Cancer Inst. 1994 May 04; 86(9):673-80. PMID: 8158698.
      Citations: 170     Fields:    Translation:HumansCTClinical Trials
    142. Bayouth JE, Macey DJ, Kasi LP, Fossella FV. Dosimetry and toxicity of samarium-153-EDTMP administered for bone pain due to skeletal metastases. J Nucl Med. 1994 Jan; 35(1):63-9. PMID: 7505819.
      Citations: 27     Fields:    Translation:HumansCTClinical Trials
    143. Goeckeler WF, Stoneburner LK, Kasi LP, Fossella FV, Price DR, Fordyce WA. Analysis of urine samples from metastatic bone cancer patients administered 153Sm-EDTMP. Nucl Med Biol. 1993 Jul; 20(5):657-61. PMID: 8358352.
      Citations: 3     Fields:    Translation:Humans
    144. Murphy WK, Fossella FV, Winn RJ, Shin DM, Hynes HE, Gross HM, Davilla E, Leimert J, Dhingra H, Raber MN, et al. Phase II study of taxol in patients with untreated advanced non-small-cell lung cancer. J Natl Cancer Inst. 1993 Mar 03; 85(5):384-8. PMID: 8094466.
      Citations: 61     Fields:    Translation:HumansCTClinical Trials
    145. Munshi NC, Seitz DE, Fossella F, Lippman SM, Einhorn LH. Phase II study of sulofenur (LY 186641). A novel antineoplastic agent in advanced non-small cell lung cancer. Invest New Drugs. 1993 Feb; 11(1):87-90. PMID: 8394298.
      Citations: 5     Fields:    Translation:HumansCTClinical Trials
    146. Fossella FV, Winn RJ, Holoye PY, Hallinan B, Raber MN, Hoelzer K, Young JA, Readling J, Bowers B, Hong WK. Phase II trial of trimetrexate for unresectable or metastatic non-small cell bronchogenic carcinoma. Invest New Drugs. 1992 Nov; 10(4):331-5. PMID: 1336771.
      Citations: 1     Fields:    Translation:HumansCTClinical Trials
    147. Lee JS, Libshitz HI, Fossella FV, Murphy WK, Pang AC, Lippman SM, Shin DM, Dimery IW, Glisson BS, Hong WK. Improved therapeutic index by leucovorin of edatrexate, cyclophosphamide, and cisplatin regimen for non-small-cell lung cancer. J Natl Cancer Inst. 1992 Jul 01; 84(13):1039-40. PMID: 1318977.
      Citations: 4     Fields:    Translation:HumansCTClinical Trials
    148. Shin DM, Dhingra HM, Lee JS, Fossella FV, Murphy WK, Hong WK. Phase II study of combination therapy with high-dose cisplatin, etoposide, and mitomycin in patients with advanced non-small-cell lung cancer. Am J Clin Oncol. 1992 Jun; 15(3):194-9. PMID: 1317094.
      Citations:    Fields:    Translation:HumansCTClinical Trials
    149. Lenzi R, Fossella FV, Lee JS. Systemic treatment of non-small-cell lung cancer. Compr Ther. 1992 Mar; 18(3):27-30. PMID: 1315236.
      Citations:    Fields:    Translation:Humans
    150. Fossella FV, Lippman SM, Seitz DE, Alberts DS, Taylor CW, Wiltshaw E, Hardy J, O'Brien M, Haynes TR, Wolen RL. Hypoprothrombinemia from coadministration of sulofenur (LY 186641) and warfarin: report of three cases. Invest New Drugs. 1991 Nov; 9(4):357-9. PMID: 1804813.
      Citations: 1     Fields:    Translation:HumansCTClinical Trials
    151. Fossella FV, Winn RJ, Holoye PY, Raber MN, Holden L, Belt R, Allen H, Hallinan B, Harper K. Phase II trial of intravenous 6-thioguanine for unresectable or metastatic non-small cell bronchogenic carcinoma. Invest New Drugs. 1991 Nov; 9(4):375-6. PMID: 1666631.
      Citations:    Fields:    Translation:HumansCTClinical Trials
    152. Lee JS, Libshitz HI, Fossella FV, Murphy WK, Pang AC, Lippman SM, Shin DM, Dimery IW, Glisson BS, Hong WK. Edatrexate improves the antitumor effects of cyclophosphamide and cisplatin against non-small cell lung cancer. Cancer. 1991 Sep 01; 68(5):959-64. PMID: 1655220.
      Citations: 3     Fields:    Translation:HumansCTClinical Trials
    153. Ellerbroek NA, Fossella FV, Rich TA, Ajani JA, Komaki R, Roth JA, Holoye PY. Low-dose continuous infusion cisplatin combined with external beam irradiation for advanced colorectal adenocarcinoma and unresectable non-small cell lung carcinoma. Int J Radiat Oncol Biol Phys. 1991 Feb; 20(2):351-5. PMID: 1846848.
      Citations: 1     Fields:    Translation:HumansCTClinical Trials
    154. Tuma SN, Orson F, Fossella FV, Waidhofer W. Seizures and dermatitis after exposure to caprolactam. Arch Intern Med. 1981 Oct; 141(11):1544-5. PMID: 7283571.
      Citations: 4     Fields:    Translation:Humans
    155. Small cell lung cancer. 63-75.
    156. Phase I study of IMGN901, a CD56-targeting antibody-drug conjugate, in patients with CD56-positive solid tumors. Investigational New Drugs. 1-10.
    157. Dexamethasone for Dyspnea in Cancer Patients. Journal of Pain and Symptom Management. 52:8-16.e1.
    158. Single-agent docetaxel in patients with refractory non-small-cell lung cancer. Oncology. 11:11-15.
    159. Paclitaxel/carboplatin chemotherapy as primary treatment of brain metastases in non-small cell lung cancer. Seminars in Oncology. 24.
    160. The BATTLE-2 study. Journal of Clinical Oncology. 34:3638-3647.
    161. Combinations of Radiation Therapy and Chemotherapy for Nonsmall Cell Lung Carcinoma. 283-314.
    FOSSELLA's Networks
    Click the
    Explore
    buttons for more information and interactive visualizations!
    Concepts (378)
    Explore
    _
    Co-Authors (123)
    Explore
    _
    Similar People (60)
    Explore
    _
    Same Department Expand Description
    Explore
    _